ArticleResearch square2026
Exploring the Association of Angiotensin-(1-7) with Left Ventricular Mass Index in Youth with Hereditary Hypophosphatemia: A Pilot Study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Introduction: Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is associated with cardiovascular-kidney-metabolic syndrome in patients with chronic kidney disease in part mediated by angiotensin II. X-linked hypophosphatemia (XLH) is characterized by phosphate wasting due to excess FGF23 activity, but its associations with angiotensin peptides and cardiovascular disease remain unclear. We evaluated cross-sectional associations between angiotensin II, angiotensin-(1-7), and left ventricular mass index (LVMI) in youth with XLH. Methods: A pilot prospective cross-sectional study enrolled youth and young adults aged 2-24 years with XLH from nephrology and endocrinology clinics at one hospital. Individuals with acquired hypophosphatemia or inability to provide urine were excluded. LVMI was collected from echocardiograms while peptides were measured in blood and urine by radioimmunoassays. We assessed associations using Spearman correlation coefficients. Results: Among seven participants, 71% were female and median age was 12.8 years [IQR 7.7-13.7]. Seventy-one percent had a pathologic Discussion: In youth and young adults with XLH, blood and urine angiotensin peptide collection was feasible, but values were not associated with LVMI, suggesting ACE/Ang II and ACE2/Ang-(1-7) may not mediate FGF23-related cardiovascular-kidney-metabolic syndrome risk if confirmed. Larger studies are needed to determine if the renin-angiotensin-aldosterone system contributes to worse outcomes in FGF23-mediated XLH and should be targeted to improve cardiovascular-kidney-metabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.